Evidence map›Paper›PMID 38035028›Full record

SynthesisFrontiers in pharmacology2023

Diagnostics and treatments of COVID-19: two-year update to a living systematic review of economic evaluations.

Jamie Elvidge, Gareth Hopkin, Nithin Narayanan, David Nicholls, Dalia Dawoud

Open access · goldAbstract readSystematic Review
In one paragraph

Synthesis in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 2 pooled it
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 syntheses or guidelines pooled it, 3 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Jamie ElvidgeScience, Evidence and Analytics Directorate, National Institute for Health and Care Excellence, Manchester, United Kingdom.
Gareth HopkinScience, Evidence and Analytics Directorate, National Institute for Health and Care Excellence, Manchester, United Kingdom.
Nithin NarayananNorwich Medical School, University of East Anglia, Norwich, United Kingdom.
David NichollsScience, Evidence and Analytics Directorate, National Institute for Health and Care Excellence, Manchester, United Kingdom.
Dalia DawoudScience, Evidence and Analytics Directorate, National Institute for Health and Care Excellence, Manchester, United Kingdom.
National Institute for Health and Care Excellence · GBUniversity of East Anglia · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

cost-effectivenesscost-utility analysisCOVID-19diagnosticseconomic evaluationhealth technology assessmentliving reviewpharmacological

Identifiers

PMID38035028
PMCPMC10687367
OpenAlexW4388734188

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.